Inhibikase Therapeutics Inc (IKT)
NASDAQ
News
Market Data
Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
The current IKT market cap is 8.58M. The company's latest EPS is USD -2.5494 and P/E is -0.45.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 116k | 80k | 0 | 0 | 0 |
| Operating Income | -6.2M | -4.77M | -4.4M | -4.78M | -5.05M |
| Net Income | -5.78M | -4.6M | -4.18M | -4.65M | -4.96M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 1.12M | 698k | 3.1M | 123k | 261k |
| Operating Income | -5.7M | -2.82M | -14.77M | -18.13M | -20.09M |
| Net Income | -5.72M | -2.85M | -14.79M | -18.05M | -19.03M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 22.35M | 17.88M | 14.51M | 11.07M | 8.83M |
| Total Liabilities | 2.88M | 2.86M | 3.53M | 4.29M | 3.73M |
| Total Equity | 19.46M | 15.02M | 10.98M | 6.78M | 5.1M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 38k | 14.78M | 42.47M | 24.94M | 14.51M |
| Total Liabilities | 4.53M | 5M | 4.05M | 3.9M | 3.53M |
| Total Equity | -4.49M | 9.78M | 38.42M | 21.04M | 10.98M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -10.54M | -14.64M | -18.09M | -3.87M | -8.92M |
| Investing | -3.29M | 13.77M | 11.66M | -3.31M | -769k |
| Financing | 8.54M | 8.54M | 8.41M | 367k | 3.61M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -338k | -1.13M | -14.3M | -17.35M | -18.09M |
| Investing | N/A | N/A | N/A | -16.01M | 11.66M |
| Financing | -23k | 15.07M | 41.09M | -205k | 8.41M |
| Market Cap | 8.58M |
| Price to Earnings Ratio | -0.45 |
| Price to Sales Ratio | 32.86 |
| Price to Cash Ratio | 0.94 |
| Price to Book Ratio | 0.78 |
| Dividend Yield | - |
| Shares Outstanding | 7.46M |
| Average Volume (1 week) | 19.58k |
| Average Volume (1 Month) | 18.73k |
| 52 Week Change | -8.73% |
| 52 Week High | 3.82 |
| 52 Week Low | 0.79 |
| Spread (Intraday) | 0.1 (8%) |
| Company Name | Inhibikase Therapeutics Inc |
| Address |
1313 n market st ste 5100 wilmington, delaware 19801 |
| Website | https://www.inhibikase.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
